PMID- 21885686 OWN - NLM STAT- MEDLINE DCOM- 20120124 LR - 20220409 IS - 1522-1547 (Electronic) IS - 0193-1857 (Linking) VI - 301 IP - 6 DP - 2011 Dec TI - Estrogen deficiency worsens steatohepatitis in mice fed high-fat and high-cholesterol diet. PG - G1031-43 LID - 10.1152/ajpgi.00211.2011 [doi] AB - Recent studies indicate an accelerated progression of nonalcoholic steatohepatitis (NASH) in postmenopausal women. Hypercholesterolemia, an important risk factor for NASH progression, is often observed after menopause. This study examined the effects of estrogen on NASH in ovariectomized (OVX) mice fed a high-fat and high-cholesterol (HFHC) diet. To investigate the effects of estrogen deficiency, OVX mice and sham-operated (SO) mice were fed normal chow or HFHC diet for 6 wk. Next, to investigate the effects of exogenous estrogen replenishment, OVX mice fed with HFHC diet were treated with implanted hormone release pellets (containing 17beta-estradiol or placebo vehicle) for 6 wk. OVX mice on the HFHC diet showed enhanced liver injury with increased liver macrophage infiltration and elevated serum cholesterol levels compared with SO-HFHC mice. Hepatocyte monocyte chemoattractant protein-1 (MCP1) protein expression in OVX-HFHC mice was also enhanced compared with SO-HFHC mice. In addition, hepatic inflammatory gene expressions, including monocytes chemokine (C-C motif) receptor 2 (CCR2), were significantly elevated in OVX-HFHC mice. Estrogen treatment improved serum cholesterol levels, liver injury, macrophage infiltration, and inflammatory gene expressions in OVX-HFHC mice. Moreover, the elevated expression of liver CCR2 and MCP1 were decreased by estrogen treatment in OVX-HFHC mice, whereas low-density lipoprotein dose dependently enhanced CCR2 expression in THP1 monocytes. Our study demonstrated that estrogen deficiency accelerated NASH progression in OVX mice fed HFHC diet and that this effect was improved by estrogen therapy. Hypercholesterolemia in postmenopausal women would be a potential risk factor for NASH progression. FAU - Kamada, Yoshihiro AU - Kamada Y AD - Department of Gastroenterology and Hepatology, Osaka University, Graduate School of Medicine, Suita, Osaka, Japan. FAU - Kiso, Shinichi AU - Kiso S FAU - Yoshida, Yuichi AU - Yoshida Y FAU - Chatani, Norihiro AU - Chatani N FAU - Kizu, Takashi AU - Kizu T FAU - Hamano, Mina AU - Hamano M FAU - Tsubakio, Mayumi AU - Tsubakio M FAU - Takemura, Takayo AU - Takemura T FAU - Ezaki, Hisao AU - Ezaki H FAU - Hayashi, Norio AU - Hayashi N FAU - Takehara, Tetsuo AU - Takehara T LA - eng PT - Journal Article DEP - 20110901 PL - United States TA - Am J Physiol Gastrointest Liver Physiol JT - American journal of physiology. Gastrointestinal and liver physiology JID - 100901227 RN - 0 (Ccl2 protein, mouse) RN - 0 (Ccr2 protein, mouse) RN - 0 (Chemokine CCL2) RN - 0 (Cholesterol, Dietary) RN - 0 (Estrogens) RN - 0 (Lipoproteins) RN - 0 (Receptors, CCR2) RN - 0 (lipoprotein cholesterol) RN - 97C5T2UQ7J (Cholesterol) SB - IM MH - Animals MH - Chemokine CCL2/genetics MH - Cholesterol/blood MH - Cholesterol, Dietary/*pharmacology MH - *Diet, High-Fat MH - Estrogens/*deficiency/pharmacology MH - Fatty Liver/drug therapy/epidemiology/*metabolism MH - Female MH - Gene Expression/physiology MH - Lipoproteins/blood MH - Liver/physiology MH - Liver Cirrhosis/drug therapy/epidemiology/metabolism MH - Macrophages/pathology/physiology MH - Mice MH - Mice, Inbred C57BL MH - Monocytes/pathology/physiology MH - Non-alcoholic Fatty Liver Disease MH - Ovariectomy MH - Postmenopause/*metabolism MH - Receptors, CCR2/genetics MH - Risk Factors EDAT- 2011/09/03 06:00 MHDA- 2012/01/25 06:00 CRDT- 2011/09/03 06:00 PHST- 2011/09/03 06:00 [entrez] PHST- 2011/09/03 06:00 [pubmed] PHST- 2012/01/25 06:00 [medline] AID - ajpgi.00211.2011 [pii] AID - 10.1152/ajpgi.00211.2011 [doi] PST - ppublish SO - Am J Physiol Gastrointest Liver Physiol. 2011 Dec;301(6):G1031-43. doi: 10.1152/ajpgi.00211.2011. Epub 2011 Sep 1.